---
document_datetime: 2025-06-13 15:08:45
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rivastigmine-actavis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: rivastigmine-actavis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.0807022
conversion_datetime: 2025-12-27 17:14:31.061514
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rivastigmine Actavis

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,youmayneed to alsorefer toEPAR-Procedural steps taken and scientific information after authorisation (archive).

| Applicationnumber   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | -Notification acc. Article 61(3) - | 13/06/2025                          |                                          | PL                              |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000278907                    | Update of the product information to align the ADRslisted in sections′4.Possible side effects'ofthepackageleafletwithsection 4.8 of the SmPC with the update of the packageleafletwiththeadditionofcontact details of local representatives.Inaddition, the marketing authorisationholder hastaken the opportunity tointroducean editorial correction throughoutPI.                                                                                                                                                                                                                                                                                                                       |            |                       |                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation typeIB/ EMA/VR/0000252948 | C.I.2Change(s)intheSummaryofProduct Characteristics,Labelling orPackageLeaflet ofageneric/hybrid/biosimilarmedicinal productsfollowingassessmentofthesame change for the reference product-C.I.2.a Implementation ofchange(s)forwhich no newadditionaldata isrequiredtobe submittedbytheMAH-Accepted Toupdatesection4.8of theSmPC to add the adversereactionPleurothotonus(Pisa syndrome) with a frequency \"not known\" undertheSoCNervoussystemdisorders. Thepackageleafletis updatedaccordingly. InadditiontheMAHhastakenthe opportunity to make minor editorial changes throughouttheannexesandhastakenthe opportunity to update the annexes to be inline with the currentQRD template. | 18/03/2025 | SmPC, Annex II and PL | Toupdatesection4.8oftheSmPCtoaddthe adversereactionPleurothotonus(Pisasyndrome) with a frequency\"not known\"under the SOC Nervoussystemdisorders.Thepackageleaflet is updated accordingly.In addition the MAH has taken the opportunity to make minor editorial changes throughout the annexes and has taken the opportunity to update the annexes to be inline with thecurrentQRDtemplate. |